Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme.
Authors
Khan, FOttensmeier, C
Popat, S
Dua, D
Dorey, N
Ellis, S
Szabo, M
Upadhyay, S
Califano, Raffaele
Chan, S
Lee, L
Ali, C
Nicolson, M
Bates, A
Button, M
Chaudhuri, A
Mulvenna, P
Shaw, H
Danson, S
Affiliation
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom.Issue Date
2014-04-09
Metadata
Show full item recordAbstract
Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.Citation
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. 2014: Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2014.03.001PubMed ID
24726055Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2014.03.001